文献速递淋巴瘤

弥漫大B细胞淋巴瘤的治疗耐药

Treatment resistance in diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2021-05-20

弥漫大B细胞淋巴瘤具有高度异质性,一线标准治疗可治愈60-70%的患者,但其余患者多出现治疗耐药且临床结局差。提高标准方案疗效的尝试(如剂量强化或添加新药)普遍未显示显著临床获益。本综述阐述DLBCL治疗耐药的概念来源,提供当前治疗耐药的分子机制最新见解,并从预防和干预角度提出管理策略。

要点

  • 一线标准治疗可治愈60-70%的DLBCL患者,其余患者多因治疗耐药而预后差。
  • 剂量强化或添加新药等提高标准方案疗效的尝试普遍未显示显著临床获益。
  • 本综述从预防和干预角度提出合理管理治疗耐药的潜在策略。

核心结论

  • 一线标准治疗可治愈60-70%的DLBCL患者,但其余患者多出现治疗耐药且临床结局差。
  • 提高标准方案疗效的尝试(如剂量强化或添加新药)普遍未显示显著临床获益。
  • 理解治疗耐药是优化耐药患者结局的迫切需求。

研究设计与样本

  • 综述:阐述DLBCL治疗耐药的概念来源,提供当前治疗耐药的分子机制最新见解,并从预防和干预角度提出管理策略。

主要发现

  • 一线标准治疗可治愈60-70%的DLBCL患者,其余患者多出现治疗耐药且临床结局差。
  • 剂量强化或添加新药等提高标准方案疗效的尝试普遍未显示显著临床获益。

临床怎么用

  • 从预防和干预角度合理管理DLBCL治疗耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents the most common subtype of lymphoma. Although 60-70% of all patients can be cured by the current standard of care in the frontline setting, the majority of the remaining patients will experience treatment resistance and have a poor clinical outcome. Numerous efforts have been made to improve the efficacy of the standard regimen by, for example, dose intensification or adding novel agents. However, these results generally failed to demonstrate significant clinical benefits. Hence, understanding treatment resistance is a pressing need to optimize the outcome of those patients. In this Review, we first describe the conceptual sources of treatment resistance in DLBCL and then provide detailed and up-to-date molecular insight into the mechanisms of resistance to the current treatment options in DLBCL. We lastly highlight the potential strategies for rationally managing treatment resistance from both the preventive and interventional perspectives.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. He MY, Kridel R. Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021. PMID: 34017074. doi:10.1038/s41375-021-01285-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。